

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

**AMENDMENT**

Subject matter to be added is in bold and underlined.

Subject matter to be deleted is in bold and strikethrough.

**BEST AVAILABLE COPY****In the Claims:**


Please enter new claims 29-43 as follows.

Please cancel claims 11-14 without prejudice or disclaimer.

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Previously presented) A compound of Formula (I):



(I)

or a stereoisomer or pharmaceutically acceptable salts, hydrates, or prodrugs thereof,  
wherein:

W is -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CR<sup>4</sup>R<sup>5</sup>-, -CR<sup>4</sup>R<sup>5</sup>CH<sub>2</sub>-, -CHR<sup>4</sup>CHR<sup>5</sup>-, -CH=CH-,

or -CR<sup>4</sup>=CR<sup>5</sup>-;

L<sub>1</sub> is -CH<sub>2</sub>-;

L<sub>2</sub> is a bond;

A is phenyl substituted with 0-3 R<sup>11</sup> and 0-1 R<sup>12</sup>, or pyridyl substituted 0-3 R<sup>11</sup>  
and 0-1 R<sup>12</sup>;

B is phenyl substituted with 0-3 R<sup>11</sup> and 0-1 R<sup>12</sup>, or pyridyl substituted with 0-3  
R<sup>11</sup> and 0-1 R<sup>12</sup>;

X<sup>1</sup>, X<sup>3</sup> and X<sup>4</sup> independently represent CR<sup>2</sup>;

X<sup>2</sup> is CR<sup>1</sup>;

R<sup>1</sup> is -C(=NH)NH<sub>2</sub>, -C(O)NH<sub>2</sub>, or -CH<sub>2</sub>NH<sub>2</sub>;

R<sup>2</sup> is H, F, Cl, Br, I, OCF<sub>3</sub>, CF<sub>3</sub>, OR<sup>a</sup>, SR<sup>a</sup>, CN, NO<sub>2</sub>, -NR<sup>7</sup>R<sup>8</sup>, -C(O)NR<sup>7a</sup>R<sup>8</sup>,

**BEST AVAILABLE COPY**

$-\text{NR}^{10}\text{C}(\text{O})\text{R}^b$ ,  $-\text{S}(\text{O})_p\text{NR}^8\text{R}^9$ ,  $-\text{S}(\text{O})\text{R}^c$ ,  $-\text{S}(\text{O})_2\text{R}^c$ ,  $\text{C}_{1-6}$  alkyl substituted with 0-2  $\text{R}^{2a}$ ,  $\text{C}_{2-6}$  alkenyl substituted with 0-2  $\text{R}^{2a}$ ,  $\text{C}_{2-6}$  alkynyl substituted with 0-2  $\text{R}^{2a}$ ,  $-(\text{CH}_2)_r\text{C}_{3-10}$  carbocycle substituted with 0-3  $\text{R}^{2b}$ , or  $-(\text{CH}_2)_r\text{5-10}$  membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$ , and substituted with 0-3  $\text{R}^{2b}$ ;

each  $\text{R}^{2a}$  is, independently at each occurrence, H, F,  $\text{OCF}_3$ ,  $\text{CF}_3$ ,  $\text{OR}^a$ ,  $\text{SR}^a$ , CN,  $-\text{NR}^7\text{R}^8$ ,  $-\text{C}(\text{O})\text{NR}^{7a}\text{R}^8$ ,  $-\text{NR}^{10}\text{C}(\text{O})\text{R}^b$ ,  $-\text{S}(\text{O})_p\text{NR}^8\text{R}^9$ ,  $-\text{S}(\text{O})\text{R}^c$ , or  $-\text{S}(\text{O})_2\text{R}^c$ ;

each  $\text{R}^{2b}$  is, independently at each occurrence, H, F, Cl, Br, I,  $\text{OR}^a$ ,  $\text{SR}^a$ , CN,  $\text{NO}_2$ ,  $\text{CF}_3$ ,  $-\text{SO}_2\text{R}^c$ ,  $-\text{NR}^7\text{R}^8$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl,  $\text{C}_{2-6}$  alkynyl,  $\text{C}_{3-6}$  cycloalkyl,  $\text{C}_{1-4}$  haloalkyl,  $\text{C}_{1-4}$  haloalkyloxy-,  $\text{C}_{1-4}$  alkyloxy-,  $\text{C}_{1-4}$  alkylthio-,  $\text{C}_{1-4}$  alkyl-C(O)-, or  $\text{C}_{1-4}$  alkyl-C(O)NH-;

$\text{R}^4$  is H, F,  $\text{OR}^a$ ,  $\text{SR}^a$ ,  $-\text{NR}^7\text{R}^8$ ,  $-\text{NR}^{10}\text{C}(\text{O})\text{NR}^{7a}\text{R}^8$ ,  $-\text{NR}^{10}\text{SO}_2\text{R}^c$ ,  $-\text{C}(\text{O})\text{OR}^a$ ,  $-(\text{CH}_2)_r\text{C}(\text{O})\text{NR}^{7a}\text{R}^8$ ,  $\text{C}_{1-4}$  haloalkyl,  $\text{C}_{1-6}$  alkyl substituted with 0-3  $\text{R}^{4a}$ ,  $\text{C}_{2-6}$  alkenyl substituted with 0-3  $\text{R}^{4a}$ ,  $\text{C}_{2-6}$  alkynyl substituted with 0-3  $\text{R}^{4a}$ ,  $-(\text{CH}_2)_r\text{C}_{3-10}$  carbocycle substituted with 0-3  $\text{R}^{4b}$ , or  $-(\text{CH}_2)_r\text{5-10}$  membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$ , and substituted with 0-3  $\text{R}^{4b}$ ;

each  $\text{R}^{4a}$  is, independently at each occurrence, H,  $\text{C}_{1-4}$  alkyl,  $\text{OR}^a$ , F, =O,  $\text{CF}_3$ , CN,  $-\text{C}(\text{O})\text{R}^a$ ,  $-\text{C}(\text{O})\text{OR}^a$ ,  $-\text{C}(\text{O})\text{NR}^{7a}\text{R}^8$ ,  $-\text{NR}^{10}\text{COR}^c$ , or  $-\text{S}(\text{O})_p\text{R}^b$ ;

each  $\text{R}^{4b}$  is, independently at each occurrence, H, OH, Cl, F, Br, I, CN,  $\text{NO}_2$ ,  $\text{CF}_3$ ,  $-\text{C}(\text{O})\text{OR}^a$ ,  $-\text{SO}_2\text{R}^c$ ,  $-\text{NR}^7\text{R}^8$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl,  $\text{C}_{2-6}$  alkynyl,  $\text{C}_{3-6}$  cycloalkyl,  $\text{C}_{1-4}$  haloalkyl,  $\text{C}_{1-4}$  haloalkyloxy-,  $\text{C}_{1-4}$  alkyloxy-,  $\text{C}_{1-4}$  alkylthio-,  $\text{C}_{1-4}$  alkyl-C(O)-,  $\text{C}_{1-4}$  alkyl-C(O)NH-,  $-\text{C}(\text{O})\text{NR}^{7a}\text{R}^8$ ,  $-\text{NR}^{10}\text{C}(\text{O})\text{R}^c$ ,  $-\text{NR}^{10}\text{S}(\text{O})_2\text{NR}^8\text{R}^9$ , or  $-\text{S}(\text{O})_2\text{NR}^8\text{R}^9$ ;

$\text{R}^5$  is H, F,  $\text{C}_{1-4}$  haloalkyl,  $\text{C}_{1-6}$  alkyl substituted with 0-3  $\text{R}^{5a}$ ,  $\text{C}_{2-6}$  alkenyl substituted with 0-3  $\text{R}^{5a}$ ,  $\text{C}_{2-6}$  alkynyl substituted with 0-3  $\text{R}^{5a}$ ,  $-(\text{CH}_2)_r\text{C}_{3-10}$  carbocycle substituted with 0-3  $\text{R}^{5b}$ , or  $-(\text{CH}_2)_r\text{5-10}$  membered heterocycle consisting of: carbon

**BEST AVAILABLE COPY**

atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>5b</sup>;

each R<sup>5a</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl, OR<sup>a</sup>, F, =O, CF<sub>3</sub>, CN, -C(O)R<sup>a</sup>, -C(O)OR<sup>a</sup>, -C(O)NR<sup>7a</sup>R<sup>8</sup>, or -S(O)<sub>p</sub>R<sup>c</sup>;

each R<sup>5b</sup> is, independently at each occurrence, H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, -C(O)OR<sup>a</sup>, -SO<sub>2</sub>R<sup>c</sup>, -NR<sup>7</sup>R<sup>8</sup>, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkyloxy-, C<sub>1-4</sub> alkyloxy-, C<sub>1-4</sub> alkylthio-, C<sub>1-4</sub> alkyl-C(O)-, or C<sub>1-4</sub> alkyl-C(O)NH-;

each R<sup>6</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl, -(CH<sub>2</sub>)<sub>r</sub>C(O)OR<sup>a</sup>, -(CH<sub>2</sub>)<sub>r</sub>S(O)<sub>2</sub>NR<sup>7a</sup>R<sup>8</sup>, or -(CH<sub>2</sub>)<sub>r</sub>OR<sup>a</sup>;

each R<sup>6a</sup> is, independently at each occurrence, H or C<sub>1-4</sub> alkyl;

each R<sup>7</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, -(CH<sub>2</sub>)<sub>n</sub>-phenyl, (C<sub>1-6</sub> alkyl)C(O)-, (C<sub>6-10</sub> aryl)-C<sub>0-4</sub> alkyl-C(O)-, (C<sub>3-6</sub> cycloalkyl)-C<sub>0-4</sub> alkyl-C(O)-, (5-10 membered heteroaryl)-C<sub>0-4</sub> alkyl-C(O)-, (C<sub>1-4</sub> alkyl)OC(O)-, (C<sub>6-10</sub> aryl)-C<sub>1-4</sub> alkyl-OC(O)-, (C<sub>1-4</sub> alkyl)-C(O)O-(C<sub>1-4</sub> alkyl)-OC(O)-, (C<sub>6-10</sub> aryl)-C(O)O-(C<sub>1-4</sub> alkyl)-OC(O)-, (5-10 membered heteroaryl)-CH<sub>2</sub>-OC(O)-, (C<sub>1-6</sub> alkyl)-NHC(O)-, (C<sub>6-10</sub> aryl)-C<sub>0-4</sub> alkyl-NHC(O)-, (5-10 membered heteroaryl)-C<sub>0-4</sub> alkyl-NHC(O)-, (C<sub>1-6</sub> alkyl)-S(O)<sub>2</sub>-, (C<sub>6-10</sub> aryl)-(C<sub>0-4</sub> alkyl)-S(O)<sub>2</sub>-, (5-10 membered heteroaryl)-C<sub>0-4</sub> alkyl-S(O)<sub>2</sub>-, (C<sub>1-6</sub> alkyl)<sub>2</sub>NC(O)-, phenyl-NHC(O)-, or (phenyl)(C<sub>1-6</sub> alkyl)NHC(O)-, wherein said phenyl, aryl and heteroaryl are substituted with 0-2 R<sup>f</sup>;

each R<sup>7a</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl substituted with 0-2 R<sup>7b</sup> and/or 0-2 R<sup>7c</sup>, -(CH<sub>2</sub>)<sub>r</sub>-C<sub>3-10</sub> carbocycle substituted with 0-3 R<sup>f</sup>, or a -(CH<sub>2</sub>)<sub>r</sub>-5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted 0-3 R<sup>f</sup>;

each R<sup>7b</sup> is, independently at each occurrence, =O, OR<sup>g</sup>, F, CN, NO<sub>2</sub>, -NR<sup>7</sup>R<sup>8</sup>, -C(O)R<sup>g</sup>, -C(O)OR<sup>g</sup>, -NR<sup>8</sup>C(O)R<sup>g</sup>, -C(O)NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>C(O)NR<sup>8</sup>R<sup>9</sup>, -SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, -NR<sup>8</sup>SO<sub>2</sub>CF<sub>3</sub>, -NR<sup>8</sup>SO<sub>2</sub>-phenyl, -S(O)<sub>2</sub>CF<sub>3</sub>,

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

**BEST AVAILABLE COPY**

$-\text{S}(\text{O})_p\text{-C}_{1-4}$  alkyl,  $-\text{S}(\text{O})_p\text{-phenyl}$ , or  $-(\text{CF}_2)_r\text{CF}_3$ ;

each  $\text{R}^{7c}$  is, independently at each occurrence,  $\text{C}_{3-10}$  carbocycle substituted with 0-3  $\text{R}^f$ ; or a 5-12 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$ , and substituted 0-3  $\text{R}^f$ ;

each  $\text{R}^8$  is, independently at each occurrence, H,  $\text{C}_{1-6}$  alkyl, or  $-(\text{CH}_2)_n\text{-phenyl}$ ;

each  $\text{R}^{8a}$  is, independently at each occurrence, H, OH,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-4}$  alkoxy,  $(\text{C}_{6-10}$  aryl)- $\text{C}_{1-4}$  alkoxy,  $-(\text{CH}_2)_n\text{-phenyl}$ ,  $(\text{C}_{1-6}$  alkyl) $\text{C}(\text{O})-$ ,  $(\text{C}_{6-10}$  aryl)- $\text{C}_{0-4}$  alkyl- $\text{C}(\text{O})-$ ,  $(\text{C}_{3-6}$  cycloalkyl)- $\text{C}_{0-4}$  alkyl- $\text{C}(\text{O})-$ ,  $(5-10$  membered heteroaryl)- $\text{C}_{0-4}$  alkyl- $\text{C}(\text{O})-$ ,  $(\text{C}_{1-4}$  alkyl) $\text{OC}(\text{O})-$ ,  $(\text{C}_{6-10}$  aryl)- $\text{C}_{1-4}$  alkyl- $\text{OC}(\text{O})-$ ,  $(\text{C}_{1-4}$  alkyl)- $\text{C}(\text{O})\text{O}-(\text{C}_{1-4}$  alkyl)- $\text{OC}(\text{O})-$ ,  $(\text{C}_{6-10}$  aryl)- $\text{C}(\text{O})\text{O}-(\text{C}_{1-4}$  alkyl)- $\text{OC}(\text{O})-$ ,  $(5-10$  membered heteroaryl)- $\text{C}_{0-4}$  alkyl- $\text{OC}(\text{O})-$ ,  $\text{C}_{1-4}$  alkoxy,  $(\text{C}_{1-4}$  alkyl) $\text{C}(\text{O})\text{O}-$ , or  $(\text{C}_{6-10}$  aryl)- $(\text{C}_{0-4}$  alkyl)- $\text{C}(\text{O})\text{O}-$ ; wherein said phenyl, aryl and heteroaryl are substituted with 0-2  $\text{R}^f$ ;

alternatively,  $\text{R}^7$  and  $\text{R}^8$ , or  $\text{R}^{7a}$  and  $\text{R}^8$ , when attached to the same nitrogen, combine to form a 5-10 membered heterocyclic ring consisting of carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$ , and optionally substituted with 0-2  $\text{R}^d$ ;

each  $\text{R}^9$  is, independently at each occurrence, H,  $\text{C}_{1-6}$  alkyl, or  $-(\text{CH}_2)_n\text{-phenyl}$ ;

each  $\text{R}^{10}$  is, independently at each occurrence, H,  $\text{C}_{1-6}$  alkyl substituted with 0-2  $\text{R}^{10a}$ ,  $\text{C}_{2-6}$  alkenyl substituted with 0-2  $\text{R}^{10a}$ ,  $\text{C}_{2-6}$  alkynyl substituted with 0-2  $\text{R}^{10a}$ ,  $-(\text{CH}_2)_r\text{-C}_{3-10}$  carbocycle substituted with 0-3  $\text{R}^d$ , or  $-(\text{CH}_2)_r\text{-5-10}$  membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$ , and substituted with 0-3  $\text{R}^d$ ;

each  $\text{R}^{10a}$  is, independently at each occurrence, H,  $\text{C}_{1-4}$  alkyl,  $\text{OR}^a$ , F, =O,  $\text{CF}_3$ , CN,  $\text{NO}_2$ ,  $-\text{C}(\text{O})\text{R}^a$ ,  $-\text{C}(\text{O})\text{OR}^a$ ,  $-\text{C}(\text{O})\text{NR}^{7a}\text{R}^8$ , or  $-\text{S}(\text{O})_p\text{R}^c$ ;

each  $\text{R}^{11}$  is, independently at each occurrence, H, =O,  $-(\text{CH}_2)_r\text{-OR}^a$ , F, Cl, Br, I,  $\text{CF}_3$ , CN,  $\text{NO}_2$ ,  $-(\text{CH}_2)_r\text{-NR}^7\text{R}^8$ ,  $-(\text{CH}_2)_r\text{-C}(=\text{NR}^8)\text{NR}^7\text{R}^9$ ,  $-\text{C}(\text{O})\text{R}^a$ ,  $-\text{C}(\text{O})\text{OR}^a$ ,


U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP**BEST AVAILABLE COPY**

$-(CH_2)_r-NR^8C(O)R^a$ ,  $-NR^8C(O)OR^c$ ,  $-NR^8CO(CH_2)_rCO_2R^a$ ,  $-C(O)NR^{7a}R^8$ ,  
 $-NR^8C(O)NR^8R^{10}$ ,  $-SO_2NR^8R^{10}$ ,  $-NR^8SO_2NR^8R^{10}$ ,  $-NR^8SO_2-C_{1-4}$  alkyl,  
 $-NR^8SO_2CF_3$ ,  $-NR^8SO_2$ -phenyl,  $-S(O)_2CF_3$ ,  $-S(O)_p-C_{1-4}$  alkyl,  $-S(O)_p$ -phenyl,  
 $-(CF_2)_rCF_3$ ,  $C_{1-6}$  alkyl substituted with 0-2  $R^{11a}$ ,  $C_{2-6}$  alkenyl substituted with 0-2  $R^{11a}$ ,  
 $C_{2-6}$  alkynyl substituted with 0-2  $R^{11a}$ ,  $C_{1-6}$  alkyl substituted with 0-2  $R^{11b}$ ,  
 $C_{2-6}$  alkenyl substituted with 0-2  $R^{11b}$ ,  $C_{2-6}$  alkynyl substituted with 0-2  $R^{11b}$ , phenyl  
substituted with 0-3  $R^c$  and/or 0-3  $R^d$ , or a 5-7 membered heterocycle consisting of  
carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>,  
and substituted with 0-3  $R^c$  and/or 0-3  $R^d$ ;

each  $R^{11a}$  is, independently at each occurrence, =O,  $OR^a$ , F, Cl, Br, I, CN,  $NO_2$ ,  
 $-NR^7R^8$ ,  $-C(O)R^a$ ,  $-C(O)OR^a$ ,  $-NR^8C(O)R^a$ ,  $-C(O)NR^{7a}R^8$ ,  $-NR^8C(O)NR^8R^{10}$ ,  
 $-SO_2NR^8R^{10}$ ,  $-NR^8SO_2NR^8R^{10}$ ,  $-NR^8SO_2-C_{1-4}$  alkyl,  $-NR^8SO_2CF_3$ ,  $-NR^8SO_2$ -phenyl,  
 $-S(O)_2CF_3$ ,  $-S(O)_p-C_{1-4}$  alkyl,  $-S(O)_p$ -phenyl, or  $-(CF_2)_rCF_3$ ;

each  $R^{11b}$  is, independently at each occurrence,  $C_{3-10}$  carbocycle substituted with  
0-3  $R^d$ , or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms  
selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted 0-3  $R^d$ ;

each  $R^{12}$  is, independently at each occurrence,  $OR^{12a}$ ,  $-CH_2OR^{12a}$ ,  
 $-C(O)NR^{7a}R^8$ ,  $-(CH_2)_rCO_2R^{12a}$ ,  $-(CH_2)_rSO_3H$ ,  $-OSO_3H$ ,  $-(CH_2)_rPO_3H$ ,  $-OPO_3H_2$ ,  
 $-PO_3H_2$ ,  $-NHCOCF_3$ ,  $-NHCO_2CF_3$ ,  $-CONHNHCO_2CF_3$ ,  $-C(CF_3)_2OH$ ,  $-SO_2NHR^{12a}$ ,  
 $-CONHCO_2NHR^{12a}$ ,  $-SO_2NHCOR^{12a}$ ,  $-SO_2NHCO_2R^{12a}$ ,  $-CONHCO_2R^{12b}$ ,  
 $-NHCO_2R^{12b}$ ,  $-CONHOR^{12b}$ ,



U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

each  $R^{12a}$  is, independently at each occurrence, H,  $C_{1-6}$  alkyl,  $-(CH_2)_r-C_{3-10}$  carbocycle substituted with 0-3  $R^d$ , or  $-(CH_2)_r-5-10$  membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$ , and substituted with 0-3  $R^d$ ;

each  $R^{12b}$  is, independently at each occurrence,  $C_{1-6}$  alkyl substituted with 0-2  $R^{12c}$ ,  $C_{2-6}$  alkenyl substituted with 0-2  $R^{12c}$ ,  $C_{2-6}$  alkynyl substituted with  $R^{12c}$ ,  $-(CH_2)_r-C_{3-10}$  carbocycle substituted with 0-3  $R^{12c}$ , or  $-(CH_2)_r-5-10$  membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$ , and substituted with 0-3  $R^{12c}$ ;

each  $R^{12c}$  is, independently at each occurrence, H, F, Cl, Br, I,  $CF_3$ ,  $OCF_3$ , CN,  $NO_2$ ,  $OR^a$ ,  $-CO_2R^a$ ,  $-NR^7R^8$ ,  $-SO_2R^c$ ,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $-(CH_2)_r-C_{3-10}$  carbocycle substituted with 0-3  $R^d$ , or  $-(CH_2)_r-5-10$  membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$ , and substituted with 0-3  $R^d$ ;

each  $R^a$  is, independently at each occurrence, H,  $C_{1-4}$  alkyl,  $-(CH_2)_r-C_{3-7}$  cycloalkyl,  $-(CH_2)_r-C_{6-10}$  aryl, or  $-(CH_2)_r-5-10$  membered heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-2  $R^f$ ;

each  $R^b$  is, independently at each occurrence,  $CF_3$ , OH,  $C_{1-4}$  alkoxy,  $C_{1-6}$  alkyl,  $-(CH_2)_r-C_{3-10}$  carbocycle substituted with 0-2  $R^d$ , or  $-(CH_2)_r-5-10$  membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$  and substituted with 0-2  $R^d$ ;

each  $R^c$  is, independently at each occurrence,  $C_{1-4}$  alkyl,  $C_{6-10}$  aryl, 5-10 membered heteroaryl,  $(C_{6-10} \text{ aryl})-C_{1-4}$  alkyl, or (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, wherein said aryl and heteroaryl groups are substituted with 0-2  $R^d$ ;

each  $R^d$  is, independently at each occurrence, H,  $=O$ ,  $OR^a$ , F, Cl, Br, I, CN,  $NO_2$ ,  $-NR^7R^8$ ,  $-C(O)R^a$ ,  $-C(O)OR^a$ ,  $-NR^8C(O)R^a$ ,  $-C(O)NR^7aR^8$ ,  $-SO_2NR^8R^9$ ,  $-NR^8SO_2NR^8R^9$ ,  $-NR^8SO_2-C_{1-4}$  alkyl,  $-NR^8SO_2CF_3$ ,  $-NR^8SO_2$ -phenyl,  $-S(O)_2CF_3$ ,  $-S(O)_p-C_{1-4}$  alkyl,  $-S(O)_p$ -phenyl,  $-(CF_2)_rCF_3$ ,  $C_{1-6}$  alkyl substituted with 0-2  $R^e$ ,

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

C<sub>2-6</sub> alkenyl substituted with 0-2 R<sup>e</sup>, or C<sub>2-6</sub> alkynyl substituted with 0-2 R<sup>e</sup>;

each R<sup>e</sup> is, independently at each occurrence, =O, OR<sup>a</sup>, F, Cl, Br, I, CN, NO<sub>2</sub>, -NR<sup>8</sup>R<sup>9</sup>, -C(O)R<sup>a</sup>, -C(O)OR<sup>a</sup>, -NR<sup>8</sup>C(O)R<sup>a</sup>, -C(O)NR<sup>7a</sup>R<sup>8</sup>, -SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, -NR<sup>8</sup>SO<sub>2</sub>CF<sub>3</sub>, -NR<sup>8</sup>SO<sub>2</sub>-phenyl, -S(O)<sub>2</sub>CF<sub>3</sub>, -S(O)<sub>p</sub>-C<sub>1-4</sub> alkyl, -S(O)<sub>p</sub>-phenyl, or -(CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>;

each R<sup>f</sup> is, independently at each occurrence, H, =O, -(CH<sub>2</sub>)<sub>r</sub>-OR<sup>g</sup>, F, Cl, Br, I, CN, NO<sub>2</sub>, -NR<sup>8</sup>R<sup>9</sup>, -C(O)R<sup>g</sup>, -C(O)OR<sup>g</sup>, -NR<sup>8</sup>C(O)R<sup>g</sup>, -C(O)NR<sup>8</sup>R<sup>9</sup>, -SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, -NR<sup>8</sup>SO<sub>2</sub>CF<sub>3</sub>, -NR<sup>8</sup>SO<sub>2</sub>-phenyl, -S(O)<sub>2</sub>CF<sub>3</sub>, -S(O)<sub>p</sub>-C<sub>1-4</sub> alkyl, -S(O)<sub>p</sub>-phenyl, -(CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl;


each R<sup>g</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, or -(CH<sub>2</sub>)<sub>n</sub>-phenyl;

n, at each occurrence, is selected from 0, 1, 2, 3, and 4;

p, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, 2, 3, and 4.

2. (Previously presented) A compound according to Claim 1, wherein the compound is of Formula (Ia):



or a stereoisomer or pharmaceutically acceptable salts, hydrates, or prodrugs thereof, wherein:

W is -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CR<sup>4</sup>R<sup>5</sup>-, -CR<sup>4</sup>R<sup>5</sup>CH<sub>2</sub>-, or -CR<sup>4</sup>=CH-;

L<sub>2</sub> is a bond;

A is phenyl substituted with 0-2 R<sup>11</sup> and 0-1 R<sup>12</sup>, or pyridyl substituted 0-2 R<sup>11</sup> and 0-1 R<sup>12</sup>;

B is phenyl substituted with 0-2 R<sup>11</sup> and 0-1 R<sup>12</sup>, or pyridyl substituted with 0-2 R<sup>11</sup> and 0-1 R<sup>12</sup>;

R<sup>1</sup> is -C(=NH)NH<sub>2</sub>, -C(O)NH<sub>2</sub>, or -CH<sub>2</sub>NH<sub>2</sub>;

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

$R^2$  is H, F,  $OR^a$ , CN,  $-NR^7R^8$ ,  $-C(O)NR^7aR^8$ ,  $-NR^{10}C(O)R^b$ ,  $-S(O)_pNR^8R^9$ ,  $-S(O)R^c$ ,  $-S(O)_2R^c$ ,  $C_{1-6}$  alkyl substituted with 0-2  $R^{2a}$ ,  $-(CH_2)_rC_{3-7}$  carbocycle substituted with 0-2  $R^{2b}$ , or  $-(CH_2)_r5-7$  membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$ , and substituted with 0-2  $R^{2b}$ ;

each  $R^{2a}$  is, independently at each occurrence, H, F,  $OCF_3$ ,  $CF_3$ ,  $OR^a$ ,  $SR^a$ , CN,  $-NR^7R^8$ ,  $-C(O)NR^7aR^8$ ,  $-S(O)_pNR^8R^9$ ,  $-NR^{10}C(O)R^b$ ,  $-S(O)_pNR^8R^9$ ,  $-S(O)R^c$ , or  $-S(O)_2R^c$ ;

each  $R^{2b}$  is, independently at each occurrence, H, F,  $OR^a$ ,  $SR^a$ , CN,  $NO_2$ ,  $CF_3$ ,  $-SO_2R^c$ ,  $-NR^7R^8$ ,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{3-6}$  cycloalkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  haloalkyloxy-,  $C_{1-4}$  alkyloxy-,  $C_{1-4}$  alkylthio-,  $C_{1-4}$  alkyl-C(O)-, or  $C_{1-4}$  alkyl-C(O)NH-;

$R^4$  is H, F,  $C_{1-4}$  haloalkyl,  $-(CH_2)_rC(O)NR^7aR^8$ ,  $C_{1-6}$  alkyl substituted with 0-3  $R^{4a}$ ,  $C_{2-6}$  alkenyl substituted with 0-3  $R^{4a}$ ,  $C_{2-6}$  alkynyl substituted with 0-3  $R^{4a}$ ,  $-(CH_2)_rC_{3-8}$  carbocycle substituted with 0-3  $R^{4b}$ , or  $-(CH_2)_r5-6$  membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$ , and substituted with 0-3  $R^{4b}$ ;

each  $R^{4a}$  is, independently at each occurrence, H,  $C_{1-4}$  alkyl,  $OR^a$ , F,  $=O$ ,  $CF_3$ , CN,  $-C(O)R^a$ ,  $-C(O)OR^a$ ,  $-C(O)NR^7aR^8$ ,  $-NR^{10}COR^c$ , or  $-S(O)_pR^b$ ;

each  $R^{4b}$  is, independently at each occurrence, H, OH, Cl, F, Cl, Br, CN,  $NO_2$ ,  $CF_3$ ,  $-C(O)OR^a$ ,  $-SO_2R^c$ ,  $-NR^7R^8$ ,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{3-6}$  cycloalkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  haloalkyloxy-,  $C_{1-4}$  alkyloxy-,  $C_{1-4}$  alkylthio-,  $C_{1-4}$  alkyl-C(O)-,  $C_{1-4}$  alkyl-C(O)NH-,  $-C(O)NR^7aR^8$ ,  $-NR^{10}C(O)R^c$ ,  $-NR^{10}S(O)_2NR^8R^9$ , or  $-S(O)_2NR^8R^9$ ;

each  $R^5$  is, independently at each occurrence, H, F,  $C_{1-4}$  haloalkyl,  $C_{1-6}$  alkyl substituted with 0-2  $R^{5a}$ ,  $C_{2-6}$  alkenyl substituted with 0-2  $R^{5a}$ ,  $C_{2-6}$  alkynyl substituted with 0-2  $R^{5a}$ ,  $-(CH_2)_rC_{3-7}$  cycloalkyl substituted with 0-2  $R^{5b}$ ,  $-(CH_2)_r$ -phenyl substituted with 0-2  $R^{5b}$ , or  $-(CH_2)_r5-6$  membered heterocycle consisting of: carbon



U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

**BEST AVAILABLE COPY**

atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted with 0-2 R<sup>5b</sup>;

each R<sup>5a</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl, OR<sup>a</sup>, F, =O, CF<sub>3</sub>, CN, -C(O)R<sup>a</sup>, -C(O)OR<sup>a</sup>, -C(O)NR<sup>7a</sup>R<sup>8</sup>, or -S(O)<sub>p</sub>R<sup>c</sup>;

each R<sup>5b</sup> is, independently at each occurrence, H, OH, Cl, F, Br, CN, NO<sub>2</sub>, CF<sub>3</sub>, -C(O)OR<sup>a</sup>, -SO<sub>2</sub>R<sup>c</sup>, -NR<sup>7</sup>R<sup>8</sup>, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkyloxy-, C<sub>1-4</sub> alkyloxy-, C<sub>1-4</sub> alkylthio-, C<sub>1-4</sub> alkyl-C(O)-, or C<sub>1-4</sub> alkyl-C(O)NH-;

each R<sup>6</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl, -(CH<sub>2</sub>)<sub>r</sub>C(O)OR<sup>a</sup>, -(CH<sub>2</sub>)<sub>r</sub>S(O)<sub>2</sub>NR<sup>7a</sup>R<sup>8</sup>, or -(CH<sub>2</sub>)<sub>r</sub>OR<sup>a</sup>;

each R<sup>6a</sup> is, independently at each occurrence, H or C<sub>1-4</sub> alkyl;

each R<sup>7</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, -(CH<sub>2</sub>)<sub>n</sub>-phenyl, (C<sub>1-6</sub> alkyl)C(O)-, (C<sub>6-10</sub> aryl)-C<sub>0-4</sub> alkyl-C(O)-, (C<sub>3-6</sub> cycloalkyl)-C<sub>0-4</sub> alkyl-C(O)-, (5-10 membered heteroaryl)-C<sub>0-4</sub> alkyl-C(O)-, (C<sub>1-4</sub> alkyl)OC(O)-, (C<sub>6-10</sub> aryl)-C<sub>1-4</sub> alkyl-OC(O)-, (C<sub>1-4</sub> alkyl)-C(O)O-(C<sub>1-4</sub> alkyl)-OC(O)-, (C<sub>6-10</sub> aryl)-C(O)O-(C<sub>1-4</sub> alkyl)-OC(O)-, (5-10 membered heteroaryl)-CH<sub>2</sub>-OC(O)-, (C<sub>1-6</sub> alkyl)-NHC(O)-, (C<sub>6-10</sub> aryl)-C<sub>0-4</sub> alkyl-NHC(O)-, (5-10 membered heteroaryl)-C<sub>0-4</sub> alkyl-NHC(O)-, (C<sub>1-6</sub> alkyl)-S(O)<sub>2</sub>-, (C<sub>6-10</sub> aryl)-(C<sub>0-4</sub> alkyl)-S(O)<sub>2</sub>-, (5-10 membered heteroaryl)-C<sub>0-4</sub> alkyl-S(O)<sub>2</sub>-, (C<sub>1-6</sub> alkyl)<sub>2</sub>NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, or (phenyl)(C<sub>1-6</sub> alkyl)NC(O)-, wherein said phenyl, aryl and heteroaryl are substituted with 0-2 R<sup>f</sup>;

each R<sup>7a</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl substituted with 0-1 R<sup>7b</sup> or 0-1 R<sup>c</sup>, C<sub>3-7</sub> cycloalkyl substituted with 0-2 R<sup>d</sup>, phenyl substituted with 0-3 R<sup>f</sup>, or a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted 0-3 R<sup>f</sup>;

each R<sup>7b</sup> is, independently at each occurrence, =O, OR<sup>g</sup>, F, Cl, Br, I, CN, NO<sub>2</sub>, -NR<sup>7</sup>R<sup>8</sup>, -C(O)R<sup>g</sup>, -C(O)OR<sup>g</sup>, -NR<sup>8</sup>C(O)R<sup>g</sup>, -C(O)NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>C(O)NR<sup>8</sup>R<sup>9</sup>, -SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, -NR<sup>8</sup>SO<sub>2</sub>CF<sub>3</sub>, -NR<sup>8</sup>SO<sub>2</sub>-phenyl,

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

$-\text{S}(\text{O})_2\text{CF}_3$ ,  $-\text{S}(\text{O})_p\text{-C}_{1-4}\text{ alkyl}$ ,  $-\text{S}(\text{O})_p\text{-phenyl}$ , or  $-(\text{CF}_2)_r\text{CF}_3$ ;

each  $\text{R}^{7c}$  is, independently at each occurrence,  $\text{C}_{3-10}$  carbocycle substituted with 0-3  $\text{R}^f$ ; or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$ , and substituted 0-3  $\text{R}^f$ ;

each  $\text{R}^8$  is, independently at each occurrence, H,  $\text{C}_{1-6}$  alkyl, or  $-(\text{CH}_2)_n\text{-phenyl}$ ;

each  $\text{R}^{8a}$  is, independently at each occurrence, H, OH,  $\text{C}_{1-6}$  alkyl,  $-(\text{CH}_2)_n\text{-phenyl}$ ,  $(\text{C}_{1-6}\text{ alkyl})\text{C}(\text{O})-$ ,  $(\text{C}_{6-10}\text{ aryl})\text{-C}_{1-4}\text{ alkyl-C}(\text{O})-$ ,  $(\text{C}_{3-6}\text{ cycloalkyl})\text{-C}_{0-4}\text{ alkyl-C}(\text{O})-$ ,  $(5-10\text{ membered heteroaryl})\text{-C}_{0-4}\text{ alkyl-C}(\text{O})-$ ,  $(\text{C}_{1-4}\text{ alkyl})\text{OC}(\text{O})-$ ,  $(\text{C}_{6-10}\text{ aryl})\text{-C}_{0-4}\text{ alkyl-OC}(\text{O})-$ ,  $(\text{C}_{1-4}\text{ alkyl})\text{-C}(\text{O})\text{O-}(\text{C}_{1-4}\text{ alkyl})\text{-OC}(\text{O})-$ ,  $\text{C}_{1-4}\text{ alkoxy}$ ,  $(\text{C}_{6-10}\text{ aryl})\text{-C}_{1-4}\text{ alkoxy}$ ,  $(\text{C}_{1-4}\text{ alkyl})\text{C}(\text{O})\text{O-}$ , or  $(\text{C}_{6-10}\text{ aryl})\text{-(C}_{0-4}\text{ alkyl})\text{-C}(\text{O})\text{O-}$ ; wherein said phenyl, aryl and heteroaryl are substituted with 0-2  $\text{R}^f$ ;

alternatively,  $\text{R}^7$  and  $\text{R}^8$ , or  $\text{R}^{7a}$  and  $\text{R}^8$ , when attached to the same nitrogen, combine to form a 5-10 membered heterocyclic ring consisting of carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$ ;

each  $\text{R}^9$  is, independently at each occurrence, H,  $\text{C}_{1-6}$  alkyl, or  $-(\text{CH}_2)_n\text{-phenyl}$ ;

each  $\text{R}^{10}$  is, independently at each occurrence, H,  $\text{C}_{1-6}$  alkyl substituted with 0-2  $\text{R}^{10a}$ ,  $\text{C}_{2-6}$  alkenyl substituted with 0-2  $\text{R}^{10a}$ ,  $\text{C}_{2-6}$  alkynyl substituted with 0-2  $\text{R}^{10a}$ ,  $(\text{C}_{1-6}\text{ alkyl})\text{C}(\text{O})-$ ,  $(\text{C}_{3-6}\text{ cycloalkyl})\text{C}_{1-3}\text{ alkyl-C}(\text{O})-$ ,  $(\text{C}_{3-6}\text{ cycloalkyl})\text{C}(\text{O})-$ , phenyl-C(O)-, benzyl-C(O)-, benzyl-S(O)<sub>2</sub>-,  $(\text{C}_{1-6}\text{ alkyl})\text{NHC}(\text{O})-$ ,  $(\text{C}_{1-6}\text{ alkyl})_2\text{NC}(\text{O})-$ , phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)( $\text{C}_{1-6}\text{ alkyl})\text{NC}(\text{O})-$ , (benzyl)( $\text{C}_{1-6}\text{ alkyl})\text{NC}(\text{O})-$ ,  $(\text{C}_{1-6}\text{ alkyl})\text{-S}(\text{O})_2-$ , phenyl-S(O)<sub>2</sub>-,  $-(\text{CH}_2)_r\text{-C}_{3-10}$  carbocycle substituted with 0-3  $\text{R}^d$ , or  $-(\text{CH}_2)_r\text{-5-10 membered heterocycle}$  consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$ , and substituted with 0-3  $\text{R}^d$ ;

each  $\text{R}^{10a}$  is, independently at each occurrence, H,  $\text{C}_{1-4}$  alkyl,  $\text{OR}^a$ , Cl, F, Cl, Br, I, =O,  $\text{CF}_3$ , CN,  $\text{NO}_2$ ,  $-\text{C}(\text{O})\text{R}^a$ ,  $-\text{C}(\text{O})\text{OR}^a$ ,  $-\text{C}(\text{O})\text{NR}^{7a}\text{R}^8$ , or  $-\text{S}(\text{O})_p\text{R}^c$ ;


U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

each  $R^{11}$  is, independently at each occurrence, H, =O,  $-(CH_2)_r-OR^a$ , F, Cl, Br, I,  $CF_3$ , CN,  $NO_2$ ,  $-(CH_2)_r-NR^7R^8$ ,  $-(CH_2)_r-C(=NR^8)NR^7R^9$ ,  $-C(O)R^a$ ,  $-C(O)OR^a$ ,  $-(CH_2)_r-NR^8C(O)R^a$ ,  $-NHC(O)(CH_2)_rC(O)OR^a$ ,  $-NR^8C(O)OR^c$ ,  $-C(O)NR^7aR^8$ ,  $-NR^8C(O)NR^8R^{10}$ ,  $-SO_2NR^8R^{10}$ ,  $-NR^8SO_2NR^8R^{10}$ ,  $-NR^8SO_2-C_{1-4}$  alkyl,  $-NR^8SO_2CF_3$ ,  $-NR^8SO_2$ -phenyl,  $-S(O)_2CF_3$ ,  $-S(O)_p-C_{1-4}$  alkyl,  $-S(O)_p$ -phenyl,  $-(CF_2)_rCF_3$ ,  $C_{1-6}$  alkyl substituted with 0-2  $R^{11a}$ ,  $C_{2-6}$  alkenyl substituted with 0-2  $R^{11a}$ ,  $C_{2-6}$  alkynyl substituted with 0-2  $R^{11a}$ ,  $C_{1-6}$  alkyl substituted with 0-2  $R^{11b}$ ,  $C_{2-6}$  alkenyl substituted with 0-2  $R^{11b}$ , or  $C_{2-6}$  alkynyl substituted with 0-2  $R^{11b}$ ;

each  $R^{11a}$  is, independently at each occurrence, =O,  $OR^a$ , F, Cl, Br, I, CN,  $NO_2$ ,  $-NR^7R^8$ ,  $-C(O)R^a$ ,  $-C(O)OR^a$ ,  $-NR^8C(O)R^a$ ,  $-C(O)NR^7aR^8$ ,  $-NR^8C(O)NR^8R^{10}$ ,  $-SO_2NR^8R^{10}$ ,  $-NR^8SO_2NR^8R^{10}$ ,  $-NR^8SO_2-C_{1-4}$  alkyl,  $-NR^8SO_2CF_3$ ,  $-NR^8SO_2$ -phenyl,  $-S(O)_2CF_3$ ,  $-S(O)_p-C_{1-4}$  alkyl,  $-S(O)_p$ -phenyl, or  $-(CF_2)_rCF_3$ ;

each  $R^{11b}$  is, independently at each occurrence,  $C_{3-10}$  carbocycle substituted with 0-3  $R^d$ , or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted 0-3  $R^d$ ;

each  $R^{12}$  is, independently at each occurrence,  $OR^{12a}$ ,  $-CH_2OR^{12a}$ ,  $-C(O)NR^7aR^8$ ,  $-(CH_2)_rCO_2R^{12a}$ ,  $-(CH_2)_rSO_3H$ ,  $-OSO_3H$ ,  $-(CH_2)_rPO_3H$ ,  $-OPO_3H_2$ ,  $-PO_3H_2$ ,  $-NHCOCF_3$ ,  $-NHSO_2CF_3$ ,  $-CONHNHSO_2CF_3$ ,  $-C(CF_3)_2OH$ ,  $-SO_2NHR^{12a}$ ,  $-CONHSO_2NHR^{12a}$ ,  $-SO_2NHCOR^{12a}$ ,  $-SO_2NHCO_2R^{12a}$ ,  $-CONHSO_2R^{12b}$ ,  $-NHSO_2R^{12b}$ ,  $-CONHOR^{12b}$ ,



each  $R^{12a}$  is, independently at each occurrence, H,  $C_{1-6}$  alkyl,  $-(CH_2)_r-C_{3-10}$  carbocycle substituted with 0-3  $R^d$ , or  $-(CH_2)_r$ -5-10 membered heterocycle consisting of

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>d</sup>;

each R<sup>12b</sup> is, independently at each occurrence, C<sub>1-6</sub> alkyl substituted with 0-2 R<sup>12c</sup>, C<sub>2-6</sub> alkenyl substituted with 0-2 R<sup>12c</sup>, C<sub>2-6</sub> alkynyl substituted with 0-2 R<sup>12c</sup>, -(CH<sub>2</sub>)<sub>r</sub>-C<sub>3-10</sub> carbocycle substituted with 0-3 R<sup>12c</sup>, or -(CH<sub>2</sub>)<sub>r</sub>-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>12c</sup>;

each R<sup>12c</sup> is, independently at each occurrence, H, F, Cl, Br, I, CF<sub>3</sub>, OCF<sub>3</sub>, CN, NO<sub>2</sub>, OR<sup>a</sup>, -CO<sub>2</sub>R<sup>a</sup>, -NR<sup>7</sup>R<sup>8</sup>, -SO<sub>2</sub>R<sup>c</sup>, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, -(CH<sub>2</sub>)<sub>r</sub>-C<sub>3-10</sub> carbocycle substituted with 0-3 R<sup>d</sup>, or -(CH<sub>2</sub>)<sub>r</sub>-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>d</sup>;

each R<sup>a</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl, -(CH<sub>2</sub>)<sub>r</sub>-C<sub>3-7</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>r</sub>-C<sub>6-10</sub> aryl, or -(CH<sub>2</sub>)<sub>r</sub>-5-10 membered heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-2 R<sup>f</sup>;

each R<sup>b</sup> is, independently at each occurrence, CF<sub>3</sub>, OH, C<sub>1-4</sub> alkoxy, C<sub>1-6</sub> alkyl, -(CH<sub>2</sub>)<sub>r</sub>-C<sub>3-10</sub> carbocycle substituted with 0-2 R<sup>d</sup>, or -(CH<sub>2</sub>)<sub>r</sub>-5-10 membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub> and substituted with 0-2 R<sup>d</sup>;

each R<sup>c</sup> is, independently at each occurrence, C<sub>1-4</sub> alkyl, C<sub>6-10</sub> aryl, 5-10 membered heteroaryl, (C<sub>6-10</sub> aryl)-C<sub>1-4</sub> alkyl, or (5-10 membered heteroaryl)-C<sub>1-4</sub> alkyl, wherein said aryl and heteroaryl groups are substituted with 0-2 R<sup>d</sup>;

each R<sup>d</sup> is, independently at each occurrence, H, =O, OR<sup>a</sup>, F, Cl, Br, I, CN, NO<sub>2</sub>, -NR<sup>7</sup>R<sup>8</sup>, -C(O)R<sup>a</sup>, -C(O)OR<sup>a</sup>, -NR<sup>8</sup>C(O)R<sup>a</sup>, -C(O)NR<sup>7a</sup>R<sup>8</sup>, -SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, -NR<sup>8</sup>SO<sub>2</sub>CF<sub>3</sub>, -NR<sup>8</sup>SO<sub>2</sub>-phenyl, -S(O)<sub>2</sub>CF<sub>3</sub>, -S(O)<sub>p</sub>-C<sub>1-4</sub> alkyl, -S(O)<sub>p</sub>-phenyl, -(CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, C<sub>1-6</sub> alkyl substituted with 0-2 R<sup>e</sup>, C<sub>2-6</sub> alkenyl substituted with 0-2 R<sup>e</sup>, or C<sub>2-6</sub> alkynyl substituted with 0-2 R<sup>e</sup>;

each  $R^e$  is, independently at each occurrence,  $=O$ ,  $OR^a$ ,  $F$ ,  $Cl$ ,  $Br$ ,  $I$ ,  $CN$ ,  $NO_2$ ,  
 $-NR^8R^9$ ,  $-C(O)R^a$ ,  $-C(O)OR^a$ ,  $-NR^8C(O)R^a$ ,  $-C(O)NR^7aR^8$ ,  $-SO_2NR^8R^9$ ,  
 $-NR^8SO_2NR^8R^9$ ,  $-NR^8SO_2-C_{1-4}$  alkyl,  $-NR^8SO_2CF_3$ ,  $-NR^8SO_2$ -phenyl,  $-S(O)_2CF_3$ ,  
 $-S(O)_p-C_{1-4}$  alkyl,  $-S(O)_p$ -phenyl, or  $-(CF_2)_rCF_3$ ;

each  $R^f$  is, independently at each occurrence,  $H$ ,  $=O$ ,  $-(CH_2)_r-OR^g$ ,  $F$ ,  $Cl$ ,  $Br$ ,  $I$ ,  
 $CN$ ,  $NO_2$ ,  $-NR^8R^9$ ,  $-C(O)R^g$ ,  $-C(O)OR^g$ ,  $-NR^8C(O)R^g$ ,  $-C(O)NR^8R^9$ ,  $-SO_2NR^8R^9$ ,  
 $-NR^8SO_2NR^8R^9$ ,  $-NR^8SO_2-C_{1-4}$  alkyl,  $-NR^8SO_2CF_3$ ,  $-NR^8SO_2$ -phenyl,  $-S(O)_2CF_3$ ,  
 $-S(O)_p-C_{1-4}$  alkyl,  $-S(O)_p$ -phenyl,  $-(CF_2)_rCF_3$ ,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl;


each  $R^g$  is, independently at each occurrence,  $H$ ,  $C_{1-6}$  alkyl, or  $-(CH_2)_n$ -phenyl;

$n$ , at each occurrence, is selected from 0, 1, 2, 3, and 4;

$p$ , at each occurrence, is selected from 0, 1, and 2; and

$r$ , at each occurrence, is selected from 0, 1, 2, 3, and 4.

3. (Previously presented) A compound according to Claim 2, wherein the compound is of Formula (Ib):



(Ib)

or a stereoisomer or pharmaceutically acceptable salts, hydrates, or prodrugs thereof,  
 wherein:

$W$  is  $-CH_2CH_2-$ ,  $-CH=CH-$ ,  $-C(benzyl)=CH-$ ,  $-C(C_{1-4} \text{ alkyl})=CH-$ ,  
 $-CH(benzyl)CH_2-$ ,  $-C(3,5\text{-diMe-benzyl})=CH-$ ,  $-C(CH_2OH)=CH-$ ,  $-C(CONHMe)=CH-$ ,  
 $-C(CONHPh)=CH-$ ,  $-C(4\text{-CO}_2\text{H-benzyl})=CH-$ , or  $-C(CH_2CONHMe)=CH-$ ;

$L_2$  is a bond;

$A$  is phenyl substituted with 0-2  $R^{11}$ , or pyridyl substituted with 0-2  $R^{11}$ ;

$B$  is phenyl substituted with 0-2  $R^{11}$  and 0-1  $R^{12}$ , or pyridyl substituted with 0-2

$R^{11}$  and 0-1  $R^{12}$ ;

$R^1$  is  $-C(=NH)NH_2$ ,  $-C(=O)NH_2$ , or  $-CH_2NH_2$ ;

**BEST AVAILABLE COPY**

~~each R<sup>7</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, or benzyl;~~

each R<sup>7a</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl substituted with 0-1 R<sup>7b</sup> or 0-1 R<sup>c</sup>, C<sub>3-7</sub> cycloalkyl substituted with 0-2 R<sup>d</sup>, phenyl substituted with 0-3 R<sup>f</sup>, or a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted 0-3 R<sup>f</sup>;

each R<sup>7b</sup> is, independently at each occurrence, =O, OR<sup>g</sup>, F, Cl, Br, I, CN, NO<sub>2</sub>, -NR<sup>7</sup>R<sup>8</sup>, -C(O)R<sup>g</sup>, -C(O)OR<sup>g</sup>, -NR<sup>8</sup>C(O)R<sup>g</sup>, -C(O)NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>C(O)NR<sup>8</sup>R<sup>9</sup>, -SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, -NR<sup>8</sup>SO<sub>2</sub>CF<sub>3</sub>, -NR<sup>8</sup>SO<sub>2</sub>-phenyl, -S(O)<sub>2</sub>CF<sub>3</sub>, -S(O)<sub>p</sub>-C<sub>1-4</sub> alkyl, -S(O)<sub>p</sub>-phenyl, or -(CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>;

each R<sup>7c</sup> is, independently at each occurrence, C<sub>3-10</sub> carbocycle substituted with 0-3 R<sup>f</sup>; or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted 0-3 R<sup>f</sup>;

each R<sup>8</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, or benzyl;

each R<sup>9</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, or benzyl;

each R<sup>11</sup> is, independently at each occurrence, H, F, Cl, CF<sub>3</sub>, C<sub>1-6</sub> alkyl, -(CH<sub>2</sub>)<sub>r</sub>OR<sup>a</sup>, CN, -(CH<sub>2</sub>)<sub>r</sub>NR<sup>7</sup>R<sup>8</sup>, -(CH<sub>2</sub>)<sub>r</sub>-C(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>, -C(O)R<sup>a</sup>, -C(O)OR<sup>a</sup>, -(CH<sub>2</sub>)<sub>r</sub>NR<sup>8</sup>C(O)R<sup>a</sup>, -NR<sup>8</sup>C(O)OR<sup>c</sup>, -C(O)NR<sup>7a</sup>R<sup>8</sup>, -NR<sup>8</sup>C(O)NR<sup>8</sup>R<sup>10</sup>, -SO<sub>2</sub>NR<sup>8</sup>R<sup>10</sup>, -NR<sup>8</sup>SO<sub>2</sub>NR<sup>8</sup>R<sup>10</sup>, or -NR<sup>8</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl;

R<sup>12</sup> is -C(O)NR<sup>7a</sup>R<sup>8</sup>, -(CH<sub>2</sub>)<sub>r</sub>CO<sub>2</sub>R<sup>12a</sup>, -CH<sub>2</sub>OR<sup>12a</sup>, -SO<sub>2</sub>NHR<sup>12a</sup>, -SO<sub>2</sub>NHCO<sub>2</sub>R<sup>12a</sup>, -SO<sub>2</sub>NHCO<sub>2</sub>R<sup>12a</sup>, -CONHSO<sub>2</sub>R<sup>12b</sup>, -NHSO<sub>2</sub>R<sup>12b</sup>, or -(CH<sub>2</sub>)<sub>r</sub>-5-tetrazolyl;

each R<sup>12a</sup> is, independently at each occurrence, H or C<sub>1-6</sub> alkyl;

each R<sup>12b</sup> is, independently at each occurrence, C<sub>1-4</sub> alkyl substituted with 0-1 R<sup>12c</sup>, C<sub>2-4</sub> alkenyl substituted with 0-1 R<sup>12c</sup>, C<sub>2-4</sub> alkynyl substituted with R<sup>12c</sup>, -(CH<sub>2</sub>)<sub>r</sub>-C<sub>3-7</sub> carbocycle substituted with 0-2 R<sup>12c</sup>, or -(CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>, and substituted with 0-2 R<sup>12c</sup>;

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

each  $R^{12c}$  is, independently at each occurrence, H, F, Cl, Br, I,  $CF_3$ ,  $OCF_3$ , CN,  $NO_2$ ,  $OR^a$ ,  $-CO_2R^a$ ,  $-NR^7R^8$ ,  $-SO_2R^c$ ,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $-(CH_2)_r-C_{3-10}$  carbocycle substituted with 0-3  $R^d$ ; or  $-(CH_2)_r-5-10$  membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$ , and substituted with 0-3  $R^d$ ;

each  $R^a$  is, independently at each occurrence, H,  $C_{1-4}$  alkyl,  $-(CH_2)_r-C_{3-7}$  cycloalkyl,  $-(CH_2)_r-C_{6-10}$  aryl, or  $-(CH_2)_r-5-10$  membered heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-2  $R^f$ ;

each  $R^c$  is, independently at each occurrence,  $C_{1-4}$  alkyl, phenyl or benzyl;

each  $R^f$  is, independently at each occurrence, H, =O,  $-(CH_2)_r-OR^g$ , F, Cl, Br,  $CF_3$ , CN,  $NO_2$ ,  $-NR^8R^9$ ,  $-C(O)R^g$ ,  $-C(O)OR^g$ ,  $-NR^8C(O)R^g$ ,  $-C(O)NR^8R^9$ ,  $-SO_2NR^8R^9$ ,  $-NR^8SO_2-C_{1-4}$  alkyl,  $-NR^8SO_2CF_3$ ,  $-S(O)_2CF_3$ ,  $-S(O)_p-C_{1-4}$  alkyl,  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl, or  $C_2-C_6$  alkynyl;

each  $R^g$  is, independently at each occurrence, H or  $C_{1-4}$  alkyl;

p, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, 2, 3, and 4.

4. (Previously presented) A compound according to Claim 3, wherein:

W is  $-CH_2CH_2-$ ,  $-CH=CH-$ ,  $-C(\text{benzyl})=CH-$ ,  $-C(C_{1-4} \text{ alkyl})=CH-$ ,  $-CH(\text{benzyl})CH_2-$ ,  $-C(3,5\text{-diMe-benzyl})=CH-$ ,  $-C(CH_2OH)=CH-$ ,  $-C(CONHMe)=CH-$ ,  $-C(CONHPh)=CH-$ ,  $-C(4-CO_2H\text{-benzyl})=CH-$ , or  $-C(CH_2CONHMe)=CH-$ ;

$L_2$  is a bond;

A is phenyl substituted with 0-2  $R^{11}$ , or pyridyl substituted with 0-2  $R^{11}$ ;

B is phenyl substituted with 0-2  $R^{11}$  and 0-1  $R^{12}$ , or pyridyl substituted with 0-2  $R^{11}$  and 0-1  $R^{12}$ ;

$R^1$  is  $-C(=NH)NH_2$ ,  $-C(=O)NH_2$ , or  $-CH_2NH_2$ ;

each  $R^{11}$  is, independently at each occurrence, H, F,  $CF_3$ ,  $C_{1-4}$  alkyl, OH,  $-CH_2OH$ , OMe, OEt, CN,  $-NH_2$ ,  $-CH_2NH_2$ ,  $-CH_2NMe_2$ ,  $-C(=NH)NH_2$ ,

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

-CH<sub>2</sub>C(=NH)NH<sub>2</sub>, -CH<sub>2</sub>NHAc, -CO<sub>2</sub>H, -CO<sub>2</sub>Me, -NHAc, -NHCOEt, -NHCOPr, -NHCO(*i*-Pr), -NHC(O)(*i*-Bu), -NHCO(phenyl), -NHCO(benzyl), -NHCO(tetrazol-5-yl), -NHCOCH<sub>2</sub>(tetrazol-5-yl), -NHCO(CH<sub>2</sub>)<sub>2</sub>(tetrazol-5-yl), -CO(1-morpholino), -CO[4-(2-OH-ethyl)-1-piperdiny], -CO[4-(2-OMe-ethyl)-1-piperdiny], -CO[4-(2-CO<sub>2</sub>Et-ethyl)-1-piperdiny], -C(O)NH<sub>2</sub>, -C(O)NHMe, -C(O)NH<sub>2</sub>Et, -C(O)NHPr, -C(O)NH(*i*-Bu), -C(O)NHisoamyl, -C(O)NH(CH<sub>2</sub>CH<sub>2</sub>N(Me)<sub>2</sub>), -CONHCH<sub>2</sub>CO<sub>2</sub>H, -CONH(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>H, -CONH(CH<sub>2</sub>)<sub>3</sub>CO<sub>2</sub>H, -CONH(CH<sub>2</sub>)<sub>3</sub>OH, -CONHcyclopropylmethyl, -CONHcyclohexylmethyl, -CONHphenyl, -CONH(benzyl), -CONHCH(Me)phenyl, -CONH(4-OMe-benzyl), -CONH(3,5-diOMe-benzyl), -CONH(4-Cl-benzyl), -CONH(phenethyl), -CONH(3-Cl-phenethyl), -CONH(phenylpropyl), -CONH[(2-pyridyl)-methyl], -CONH[(3-pyridyl)-methyl], -CONH[2-(2-pyridyl)-ethyl], -CONHCH<sub>2</sub>(4-tetrahydropyranyl), -CONHCH<sub>2</sub>(1-indanyl), -CONH(1-naphthyl), -NHSO<sub>2</sub>Me, or -NHSO<sub>2</sub>Et; and

R<sup>12</sup> is OH, -CH<sub>2</sub>OH, -CO<sub>2</sub>H, -CH<sub>2</sub>(CO<sub>2</sub>H), -CO<sub>2</sub>Me, -SO<sub>2</sub>NH<sub>2</sub>, or -CONH<sub>2</sub>.

5. (Previously amended) A compound according to Claim 4, wherein:  
W is -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, -C(benzyl)=CH-, -CH(benzyl)CH<sub>2</sub>-, or -C(C<sub>1-4</sub> alkyl)=CH-;

L<sub>2</sub> is a bond;

A is 1,2-phenylene, 3-carboxy-1,2-phenylene, 4-methyl-1,2-phenylene, 4-methoxy-1,2-phenylene, 4-aminomethyl-1,2-phenylene, 4-amidino-1,2-phenylene, 4-amidinomethyl-1,2-phenylene, 4-acetoamidomethyl-1,2-phenylene, 5-(N,N-dimethylaminoethylcarbamoyl)-1,2-phenylene, 5-carboxy-1,2-phenylene, 5-hydroxymethyl-1,2-phenylene, 5-acetylamino-1,2-phenylene, 5-propionylamino-1,2-phenylene, 5-butyrylamino-1,2-phenylene, 5-(3-methylbutyrylamino)-1,2-phenylene, 5-(2,2-dimethylpropionylamino)-1,2-phenylene,



U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

5-benzylcarbonylamino-1,2-phenylene, 4-methoxy-5-hydroxy-1,2-phenylene,  
5-carbamoyl-1,2-phenylene, 5-methylcarbamoyl-1,2-phenylene,  
5-ethylcarbamoyl-1,2-phenylene, 5-propylcarbamoyl-1,2-phenylene,  
5-isopropylcarbamoyl-1,2-phenylene, 5-isobutylcarbamoyl-1,2-phenylene,  
5-*t*-butylcarbamoyl-1,2-phenylene, 5-isoamylcarbamoyl-1,2-phenylene,  
5-carboxymethylcarbamoyl-1,2-phenylene, 5-(2-carboxyethyl)carbamoyl-1,2-phenylene,  
5-(3-hydroxypropyl)carbamoyl-1,2-phenylene,  
5-(3-carboxypropyl)carbamoyl-1,2-phenylene,  
5-cyclopropylmethylcarbamoyl-1,2-phenylene,  
5-cyclohexylmethylcarbamoyl-1,2-phenylene, 5-phenylcarbamoyl-1,2-phenylene,  
5-benzylcarbamoyl-1,2-phenylene, 5-(1-phenylethyl)carbamoyl-1,2-phenylene,  
5-phenethylcarbamoyl-1,2-phenylene, 5-(3-phenylpropylcarbamoyl)-1,2-phenylene,  
5-(4-methoxybenzyl)carbamoyl-1,2-phenylene,  
5-(3,5-dimethoxybenzyl)carbamoyl-1,2-phenylene,  
5-(4-chlorobenzyl)carbamoyl-1,2-phenylene,  
5-[2-(3-chlorophenyl)ethyl]carbamoyl-1,2-phenylene,  
5-(2-pyridylmethyl)carbamoyl-1,2-phenylene,  
5-(3-pyridylmethyl)carbamoyl-1,2-phenylene,  
5-[2-(2-pyridyl)ethyl]carbamoyl-1,2-phenylene,  
5-(4-tetrahydropyranyl)methylcarbamoyl-1,2-phenylene,  
5-(morpholine-4-carbonyl)-1,2-phenylene,  
5-[4-(2-hydroxyethyl)-piperidine-1-carbonyl]-1,2-phenylene,  
5-[4-(2-methoxyethyl)-piperidine-1-carbonyl]-1,2-phenylene,  
5-[4-(ethoxycarbonylmethyl)-piperidine-1-carbonyl]-1,2-phenylene,  
5-(1-naphthyl)carbamoyl-1,2-phenylene, 5-(1-indanyl)carbamoyl-1,2-phenylene,  
1,3-phenylene, 5-amino-1,3-phenylene, 5-acetylamino-1,3-phenylene,  
5-propionylamino-1,3-phenylene, 5-butyrylamino-1,3-phenylene,  
5-(3-methylbutyrylamino)-1,2-phenylene,  
5-(2,2-dimethylpropionylamino)-1,2-phenylene, or 6-amino-2,3-pyridylene; wherein the  
attachment to L<sub>2</sub> is at carbon 1 of said phenylene rings;

B is 2-carboxy-phenyl, 2-aminosulfonyl-phenyl, 3-carboxymethyl-phenyl,

~~2,4-dicarboxy-phenyl, 2,4-dimethoxycarbonyl-phenyl, 2,4-dicarbamoyl-phenyl,~~  
 2-carboxy-4-methoxycarbonyl-phenyl, 2-carboxy-4-methyl-phenyl,  
 2-carboxy-4-methoxy-phenyl, 2-carboxy-4-ethoxy-phenyl, 2-carboxy-4-flouro-phenyl,  
 2-carboxy-4-amino-phenyl, 2-carboxy-4-cyano-phenyl, 2-carboxy-4-acetylamino-phenyl,  
 2-carboxy-4-carbamoyl-phenyl, 2,5-dicarboxy-phenyl, 2,5-dicarboxy-4-methoxy-phenyl,  
 2-carboxy-4,5-dimethoxy-phenyl, 2-carboxy-4-triflouromethyl-phenyl,  
 5-carboxy-4-methoxy-phenyl, 3-carboxy-4-pyridyl, or 2-carboxy-6-methoxy-3-pyridyl;  
 and

$R^1$  is  $-C(=NH)NH_2$ ,  $-C(=O)NH_2$ , or  $-CH_2NH_2$ .

6. (Original) A compound of Claim 1 selected from:

2'-(5-carbamimidoyl-2,3-dihydroindol-1-ylmethyl)-biphenyl-2-carboxylic acid;  
 2'-(5-carbamimidoyl-2,3-dihydroindol-1-ylmethyl)-biphenyl-2,4-dicarboxylic  
 acid;  
 2'-(5-carbamimidoyl-2,3-dihydroindol-1-ylmethyl)-4-isobutylcarbamoyl-  
 biphenyl-2-carboxylic acid;  
 2'-(5-carbamimidoyl-2,3-dihydroindol-1-ylmethyl)-4-methoxybiphenyl-2-  
 carboxylic acid;  
 4-acetylamino-2'-(5-carbamimidoyl-2,3-dihydroindol-1-ylmethyl)-biphenyl-2-  
 carboxylic acid;  
 2'-(5-carbamimidoyl-2,3-dihydroindol-1-ylmethyl)-4'-methoxy-biphenyl-2-  
 carboxylic acid;  
 2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-carbamoyl-biphenyl-2-  
 carboxylic acid;  
 3'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-biphenyl-2-carboxylic acid;  
 3'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-biphenyl-2,4-dicarboxylic  
 acid;  
 1-(2'-sulfamoyl-biphenyl-3-ylmethyl)-2,3-dihydro-1H-indole-5-carboxamidine;  
 [2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-biphenyl-3-yl]-acetic acid;

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

5'-acetyl-amino-2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-phenethylcarbamoyl-biphenyl-2-carboxylic acid;

5'-benzylcarbamoyl-2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(3-phenylpropylcarbamoyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(2-pyridin-2-ylethylcarbamoyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-phenethylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-(3-chlorophenethyl)carbamoyl-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-indol-1-ylmethyl)-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-5'-phenethylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-phenethylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-3,4-dihydro-2H-quinolin-1-ylmethyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-phenethylcarbamoyl-biphenyl-2-carboxylic acid;

5'-benzylcarbamoyl-2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-phenethylcarbamoyl-biphenyl-2-carboxylic acid;

5'-benzylcarbamoyl-2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;  
2-benzyloxy-5-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-benzoic acid;  
2-benzyloxy-3-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-benzoic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-4'-methyl-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-4'-methyl-biphenyl-2-carboxylic acid;  
2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-4'-methyl-biphenyl-2-carboxylic acid;  
2'-(3-benzyl-5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-4'-methyl-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-5'-(2-pyridin-2-ylethylcarbamoyl)-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-ethoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-fluoro-biphenyl-2-carboxylic acid;  
5'-benzylcarbamoyl-2'-(5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;  
2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4'-carbamimidoyl-4-methoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-phenylacetyl-amino-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;  
6'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2,3'-dicarboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4,5-dimethoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methyl-biphenyl-2-carboxylic acid;

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

2'-(5-carbamimidoyl-indol-1-ylmethyl)-5'-[2-(3-chloro-phenyl)-ethylcarbamoyl]-4-methoxy-biphenyl-2-carboxylic acid;

6'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-biphenyl-2,3'-dicarboxylic acid;

2'-(5-carbamimidoyl-indol-1-ylmethyl)-4-carbamoyl-biphenyl-2-carboxylic acid;

4'-aminomethyl-2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

4'-(acetyl-amino-methyl)-2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4'-carbamimidoyl-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-propylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-5'-propylcarbamoyl-biphenyl-2-carboxylic acid;

2'-[5-carbamimidoyl-3-(3,5-dimethyl-benzyl)-indol-1-ylmethyl]-4-methoxy-biphenyl-2-carboxylic acid;

4'-aminomethyl-2'-(3-benzyl-5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-[5-carbamimidoyl-3-(3,5-dimethyl-benzyl)-2,3-dihydro-indol-1-ylmethyl]-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-indol-1-ylmethyl)-5'-(carboxymethyl-carbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(carboxymethyl-carbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-indol-1-ylmethyl)-biphenyl-2,5-dicarboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-biphenyl-2,5-dicarboxylic acid;

5'-benzylcarbamoyl-2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methyl-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-trifluoromethyl-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoylindol-1-ylmethyl)-4-methoxy-biphenyl-2,5-dicarboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methyl-5'-propylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(cyclohexylmethylcarbamoyl)-4-methyl-biphenyl-2-carboxylic acid;

2-[6-amino-2-(5-carbamimidoyl-indol-1-ylmethyl)-pyridin-3-yl]-5-methoxybenzoic acid;

2-[6-amino-2-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-pyridin-3-yl]-5-methoxy-benzoic acid;

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-5'-carbamoyl-4-methoxy-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-5'-methylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methyl-5'-[(pyridin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-isobutylcarbonylamino-4-methoxy-biphenyl-2-carboxylic acid;

5'-benzylcarbamoyl 2'-(5-carbamimidoyl-indol-1-ylmethyl)-4-methyl-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-3-methylcarbamoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-3-phenylcarbamoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(3,5-dimethoxybenzylcarbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-[(naphthalen-1-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

**BEST AVAILABLE COPY**

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(2-carboxy-ethylcarbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-biphenyl-2,5-dicarboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-(4-methoxy-benzylcarbamoyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-3-hydroxymethyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(cyclopropylmethyl-carbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(4-chloro-benzylcarbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methyl-5'-methylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-carbamoyl-5'-methylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2,5-dicarboxylic acid;

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-5'-methylcarbamoyl-biphenyl-2,5-dicarboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-(morpholine-4-carbonyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-[4-(2-methoxy-ethyl)-piperazine-1-carbonyl]-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-isobutylcarbamoyl-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-(3-methyl-butylcarbamoyl)-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-[(pyridin-3-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

**BEST AVAILABLE COPY**

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-  
[(tetrahydropyran-4-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-[4-  
(ethoxycarbonylmethyl)]-piperazine-1-carbonyl-4-methoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-biphenyl-2,6-dicarboxylic  
acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-((S)-1-phenyl-  
ethylcarbamoyl)-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-5'-((R)-1-phenyl-  
ethylcarbamoyl)-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(indan-1-ylcarbamoyl)-4-  
methoxy-biphenyl-2-carboxylic acid;  
2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-5'-ethylcarbamoyl-4-methoxy-  
biphenyl-2-carboxylic acid;  
2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-5'-propylcarbamoyl-  
biphenyl-2-carboxylic acid;  
2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-5'-(cyclopropylmethyl-  
carbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;  
2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-5'-isobutylcarbamoyl-4-  
methoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(3-  
hydroxypropylcarbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-methylcarbamoyl-4-  
methoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(3-  
carboxypropylcarbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(4-(2-hydroxyethyl)-  
piperazine-1-carbonyl)-4-methoxy-biphenyl-2-carboxylic acid;  
2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-[2-(N,N-  
dimethylamino)ethyl]carbamoyl-4-methoxy-biphenyl-2-carboxylic acid;



U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

2'-(3-benzyl-5-carbamimidoyl-indol-1-ylmethyl)-5'-methylcarbamoyl-4-methoxy-biphenyl-3-carboxylic acid;

2'-(3-(4-carboxybenzyl)-5-carbamimidoyl-indol-1-ylmethyl)-4-methoxy-5'-methylcarbamoyl-biphenyl-2-carboxylic acid;

3-{2-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5-[(pyridin-2-ylmethyl)-carbamoyl]-phenyl}-6-methoxy-pyridine-2-carboxylic acid;

2'-(5-carbamimidoyl-3-methylcarbamoylmethyl-indol-1-ylmethyl)-5'-methylcarbamoyl-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-5'-[(pyridin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

3'-(5-carbamimidoyl-2,3-dihydro-indol-1-ylmethyl)-4-carbamoyl-biphenyl-2-carboxylic acid;

4-{2-[5-carbamimidoylindol-1-ylmethyl)-5-[(pyridin-2-ylmethyl)-carbamoyl]-phenyl}-nicotinic acid;

2'-(5-carbamoyl-2,3-dihydro-indol-1-ylmethyl)-5'-(3-chlorophenethyl-carbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

5'-benzylcarbamoyl-2'-(5-carbamoyl-2,3-dihydro-indol-1-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2'-(5-aminomethyl-3-benzyl-indol-1-ylmethyl)-4-methyl-5'-methylcarbamoyl-biphenyl-2-carboxylic acid; and

2'-(5-carbamimidoyl-3-benzyl-indol-1-ylmethyl)-5'-dimethylcarbamoyl-4-methoxy-biphenyl-2-carboxylic acid;

or a stereoisomer or a pharmaceutically acceptable salt, hydrate or prodrug form thereof.

7. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

8. (Original) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

9. (Original) A method according to Claim 8, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

10. (Original) A method according to Claim 9, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

11- 23. (Canceled)

24. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt or hydrate thereof.

25. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt or hydrate thereof.

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

26. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt or hydrate thereof.
27. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt or hydrate thereof.
28. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt or hydrate thereof.
29. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt or hydrate thereof.
30. (New) A method according to Claim 29, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.
31. (New) A method according to Claim 30, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

**BEST AVAILABLE COPY**

32. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt or hydrate thereof.

33. (New) A method according to Claim 32, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

34. (New) A method according to Claim 33, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

35. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt or hydrate thereof.

36. (New) A method according to Claim 35, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

37. (New) A method according to Claim 36, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke,

~~atherosclerosis, peripheral occlusive arterial disease, venous thrombosis,~~ deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

38. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt or hydrate thereof.

39. (New) A method according to Claim 38, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

40. (New) A method according to Claim 39, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

41. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt or hydrate thereof.

U.S. Serial No. 10/824,025  
Docket No.: PH-7497-NP

42. (New) A method according to Claim 41, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

43. (New) A method according to Claim 42, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.